Adding Ebola to the Fda Priority Review Voucher Program Actby Representative Gus M. Bilirakis
Posted on 2014-12-03
BILIRAKIS. Mr. Speaker, I ask unanimous consent to take from the
Speaker's table the bill (S. 2917) to expand the program of priority
review to encourage treatments for tropical diseases, and ask for its
immediate consideration in the House.
The Clerk read the title of the bill.
The SPEAKER pro tempore. Is there objection to the request of the gentleman from Florida? There was no objection.
The text of the bill is as follows: S. 2917 Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE.
This Act may be cited as the ``Adding Ebola to the FDA Priority Review Voucher Program Act''.
SEC. 2. PRIORITY REVIEW TO ENCOURAGE TREATMENTS FOR TROPICAL DISEASES.
Section 524 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360n) is amended-- (1) in subsection (a)(3)-- (A) by redesignating subparagraph (Q) as subparagraph (R); (B) by inserting after subparagraph (P) the following: ``(Q) Filoviruses.''; and (C) in subparagraph (R), as so redesignated, by striking ``regulation by'' and inserting ``order of''; and (2) in subsection (b)-- (A) in paragraph (2), by adding ``There is no limit on the number of times a priority review voucher may be transferred before such voucher is used.'' after the period at the end; and (B) in paragraph (4), by striking ``365 days'' and inserting ``90 days''.
The bill was ordered to be read a third time, was read the third time, and passed, and a motion to reconsider was laid on the table.